A novel blood collection device stabilizes cell-free RNA in blood during sample shipping and storage by Jianbing Qin et al.
Qin et al. BMC Research Notes 2013, 6:380
http://www.biomedcentral.com/1756-0500/6/380TECHNICAL NOTE Open AccessA novel blood collection device stabilizes cell-free
RNA in blood during sample shipping and storage
Jianbing Qin1*, Thomas L Williams2 and M Rohan Fernando1Abstract
Background: Cell-free RNA (cfRNA) naturally occurs in blood and has clinical significance. Accurate quantification
of these extracellular RNAs in whole blood is hindered by the simultaneous unintended release of cellular RNA and
degradation of cfRNA after blood draw. An appropriate blood collection device is needed to stabilize cfRNA during
blood processing, transportation and storage, which will ensure cfRNA test reliability. In this study we compared a
novel blood collection device against traditional K3EDTA tubes for its ability to stabilize cfRNA in blood when
subjected to conditions that can occur during sample storage and shipping.
Findings: Shipping blood samples drawn into K3EDTA tubes showed a significant increase in mRNA copy numbers
for β-actin, c-fos, and 18S rRNA in plasma. In contrast, shipping blood drawn into Cell-Free RNA BCT™s (BCTs)
showed only a slight change in mRNA copy numbers for circulating β-actin, c-fos, and 18S rRNA. Moreover, blood
stored in K3EDTA tubes at 6°C, 22°C and 30°C for 3 days showed a significant increase in mRNA copy numbers for
c-fos and β-actin, whereas samples stored in BCTs only showed a slight increase.
Conclusion: Our results show that BCTs minimize increases in background RNA levels caused by temperature
fluctuations or agitation that can occur during blood sample storage and shipping. This novel blood collection tube
could provide a method for obtaining high quality stabilized cfRNA samples for rare RNA target detection and
determining accurate cfRNA concentrations.
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Real-time polymerase chain reactionBackground
The existence of cell-free nucleic acids in blood has been
known for a long time [1]. Evidence accumulated in
recent decades indicates that changes in the levels of
circulating nucleic acids are associated with certain disease
conditions and could be useful for clinical applications,
particularly for cancer patients and pregnant women [2].
In 1999, the circulating cell-free RNAs (cfRNAs) were first
detected in the plasma or serum of patients with nasopha-
ryngeal carcinoma [3] and malignant melanoma [4]. Later,
the investigation was expanded to patients with breast
cancer [5], colorectal cancer, follicular lymphoma [6], and
hepatocellular carcinoma [7]. Subsequent to the discovery
of cfRNA in cancer patients, circulating fetal RNA was
also found in maternal blood by Poon et al. in 2000 [8].* Correspondence: jqin@streck.com
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reproduction in any medium, provided the orSince then, other fetal/placental-specific cfRNAs were also
reported including human placental lactogen, the β-subunit
of human chorionic gonadotropin, and corticotrophin-
releasing hormone [9]. These findings have implicated
cfRNAs as blood biomarkers for the screening or diagnosis
of diseases like cancer and the monitoring of therapy. It
also provides the opportunity for early, noninvasive prenatal
genetic testing.
When employing cfRNA, however, it is important to
minimize release of cellular RNA following blood draw
since cfRNA targets present at low quantities [10]. Pre-
analytical conditions can affect the release of back-
ground RNA into plasma, decreasing the proportion of
specific cfRNA targets and masking their detection in
downstream applications. Therefore, it is necessary to
address pre-analytical issues that arise during the time
between blood draw and RNA isolation. These include
delays in blood processing, specimen storage tempera-
ture, agitation of the samples during transport and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lease from lysed nucleated blood cells and subsequently
alter cfRNA levels circulating in plasma. Thus, in order
to obtain reproducible cell-free gene transcript results, it
is essential to standardize pre-analytical phase of blood
handling using a feasible blood collection device which
is capable of stabilizing cfRNA concentration.
We previously reported that we developed a new
blood collection device, Cell-Free RNA BCT™ (BCT).
The novel chemical cocktail contained in the new device
allows for the stabilization of cfRNA in blood samples at
room temperature [11]. The goal of the present study
was to evaluate the ability of this new blood collection
device to stabilize cfRNA and minimize background
RNA release when subjected to pre-analytical variables
that can occur during sample storage and shipping. The
effect of shipping and storage temperature on plasma
cfRNA levels in blood collected into BCT or K3EDTA
tubes have been determined in this study.
Methods
Blood sample collection
This study was approved by the institutional review
board of the Methodist Hospital, Omaha, NE, USA and
informed consent was obtained from all donors prior to
blood draw. Blood specimens were collected from appa-
rently healthy adult donors by standard phlebotomy
techniques.
For each experiment, blood samples were drawn into
two different blood collection tubes. Control samples
were drawn into K3EDTA tubes (BD Vacutainer®, Becton
Dickinson, Franklin Lakes, NJ) and compared to samples
drawn into Cell-Free RNA BCT™ (Streck Inc., Omaha,
NE). Blood was mixed immediately after the draw by
inverting 10 times each.
Sample processing
Plasma was separated from blood within 2 h post collec-
tion (day 0) or after 3 days as noted. To separate plasma,
blood samples were centrifuged at 300 × g for 20 min at
room temperature. The upper plasma layer was carefully
removed without disturbing the buffy coat and transferred
to a new tube that was then centrifuged at 5000 × g
for 10 min. The cell-free plasma was then transferred
to a new tube for storage at −80°C until cfRNA
isolation.
cfRNA isolation from plasma
The cfRNA was isolated and purified from plasma using
the QIAamp® Circulating Nucleic Acid Kit (Qiagen,
Santa Clarita, CA). The manufacturer’s recommended
protocol was slightly modified by increasing the duration
of the Proteinase K treatment at 60°C from 30 min to 1 h.
An on-column DNase treatment step was included toremove DNA and cfRNA was eluted in 60 μl of nuclease
free water that was passed over the column two times.
RNA was stored at −80°C until use.
Reverse transcription quantitative real-time PCR (RT-qPCR)
All primers were purchased from Integrated DNA Tech-
nologies (IDT) (Coralville, IA). All probes for TaqMan®
assays were purchased from Applied Biosystems (Foster
City, CA), except for β-actin, which was purchased from
IDT. Primers and probe for the quantification by RT-
qPCR of c-fos mRNA, β-actin mRNA and 18S rRNA
were prepared as previously described [11]. To perform
RT-qPCR, a TaqMan® RNA-to-CT™ 1-Step Kit was
purchased from Applied Biosystems (Foster City, CA).
Plasmid DNA constructs were prepared by cloning a
DNA fragment into Zero Blunt TOPO (Invitrogen,
Carlsbad, CA), with each construct containing a single
copy of human c-fos or 18S rRNA. The resulting
amplicons had lengths of 67 bp and 105 bp, respectively.
These plasmid constructs were used to plot the standard
curves except for β-actin, which required a synthetic
oligonucleotide (Ultramer™ Oligo) that was purchased
from IDT. This produced an 86 bp amplicon.
Effect of shipping on cfRNA concentration in blood samples
For shipping study, blood was drawn from 10 donors.
Blood was drawn from each donor into three 10 mL
K3EDTA tubes and three 10 mL Cell-Free RNA BCT™
(BCT). One K3EDTA tube and one BCT from each
donor were processed within 2 h of blood draw. Another
K3EDTA tube and BCT from each donor were shipped
at ambient temperature in a box with a temperature
tracking device from Omaha, NE to a laboratory in
Springfield, MA and back during the course of two days.
The remaining K3EDTA tube and BCT from each donor
were kept at 22°C for three days and processed with the
returned shipped blood tubes. Total cfRNA was isolated
from plasma and RT-qPCR was used to quantify mRNAs
for c-fos, β-actin and 18S rRNA.
Effect of storage temperature on cfRNA concentration in
blood samples
To study the effect of storage temperature on cfRNA
concentration, blood samples were collected from 10
donors into four K3EDTA tubes and four BCTs each.
For each donor, one K3EDTA tube and one BCT were
immediately processed to separate plasma from blood by
centrifugation. These samples are subsequently referred
to as K3EDTA initial and BCT initial. The remaining
samples were stored at 6°C, 22°C or 30°C for 3 days,
respectively. Total plasma cfRNA was extracted and
mRNAs for c-fos and β-actin were measured by
RT-qPCR.
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Statistical analysis was carried out using Microsoft Excel for
Office 2007. Paired Student’s t-test was used and p < 0.05
was considered statistically significant. Fold change calcula-
tions were determined as previously described [12].
Findings
Effect of shipping on cfRNA concentration in blood
samples
To determine the effect of transportation on cell-free
RNA analysis, we collected parallel blood samples from
healthy donors into the novel sample collection tubes
and control K3EDTA tubes. As described previously,
blood specimens were either shipped from Omaha NE
to a laboratory in Springfield MA and back or not
shipped and left at 22°C. Temperature inside the sample
box was monitored during the shipment using a digital
temperature logger (Omega Nomad, Omega Engineer-
ing, Stamford, CT). The samples shipped at ambient
temperature were exposed to temperatures ranging from
14.9 to 28.5°C with an average of 21.5°C during the
round trip shipping (Figure 1).
Three days post blood draw, both shipped and not
shipped blood specimens were processed for cell-free
RNA analyses and compared with initial samples which
were processed immediately after blood collection
(within 2 h). Figure 2A shows the results of shipping of
blood when drawn into K3EDTA tubes on the cell-free
c-fos mRNA concentration. Initially, the median cell-free
c-fos mRNA concentration was found to be 92 copies
per mL of plasma (copies/mL) that increased markedly
in not shipped (stored at room temperature for 3 days)
and shipped blood samples. Compared to the initial
value, statistically significant increases were observed in




















Figure 1 Shipping temperature record. A digital temperature logger wa
transportation from Omaha NE to Springfield MA and back. The samples w
overnight delivery. As shown in the graph, the samples were retuned back
range of 14.9 – 28.5°C.(77-fold increase, p = 0.0002) and shipped (901-fold
increase, p = 0.0056) blood collected into K3EDTA
tubes. Figure 2A also illustrates the effect of shipping of
blood drawn into BCTs on the cell-free c-fos mRNA
concentration in blood. Here, compared to the initial
value, there were only slight increases in the cell-free
c-fos mRNA concentration in not shipped (3-fold in-
crease, p = 0.17) and shipped (5-fold increase, p = 0.024)
blood collected into BCTs. Analysis of β-actin mRNA
and 18s rRNA also showed results similar to c-fos
mRNA. Figure 2B shows the results of shipping of blood
when drawn into K3EDTA tubes on the cell-free β-actin
mRNA concentration. Compared to initial β-actin mRNA
concentration, large increases were observed in the cell-
free β-actin mRNA concentration in non-shipped (35-fold
increase, p = 0.053) and shipped (107-fold increase,
p = 0.023) blood collected into K3EDTA tubes. Figure 2B
also shows the results of shipping of blood drawn into
BCTs on the cell-free β-actin mRNA concentration. In
BCTs, compared to initial value, there were only slight
increases in the cell-free β-actin mRNA concentration in
not shipped (2-fold increase, p = 0.003) and shipped
(4-fold increase, p = 0.01) blood. Figure 2C illustrates the
results of shipping of blood drawn into K3EDTA tubes on
the cell-free 18S rRNA concentration. Compared to initial
18S rRNA concentration, statistically significant increases
were observed in the cell-free 18S rRNA concentration in
not shipped (41-fold increase, p = 0.006) and shipped
(251-fold increase, p = 0.009) blood collected into
K3EDTA tubes. Figure 2C also shows the results of
shipping of blood drawn into BCTs on the cell-free 18S
rRNA concentration. BCTs showed slight increases in the
cell-free 18S rRNA concentration in not shipped (4-fold
increase, p = 0.004) and shipped (7-fold increase, p =
0.002) blood.24 32 40 48
)
s included inside the sample box to monitor the temperature during
ere shipped at ambient temperature without any gel packs via FedEx®
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Figure 2 (See legend on next page.)
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Figure 2 Effect of shipping on cfRNA concentration in blood samples. Blood was drawn into K3EDTA tubes and BCTs and either shipped
round trip to a lab in Springfield MA or not shipped (n = 10). On day 3, plasma from shipped and non-shipped samples was isolated and cfRNA
concentrations were determined by measuring c-fos mRNA (A), β-actin mRNA (B) and 18S rRNA (C) using RT-qPCR. Overall, the BCTs prevent
cfRNA concentrations from significant increases as compared to the K3EDTA tubes during transportation and room temperature storage. Box
plots show the median (line inside the box) and 75th and 25th percentiles (limits of the box). The upper and lower error bars indicate the 90th
and 10th percentiles, respectively. The upper most and lower most dots indicate the maximum and minimum values.
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blood samples
To demonstrate the effect of temperature on cfRNA
levels in blood drawn into K3EDTA tubes and BCTs,
samples were stored at 6°C, 22°C or 30°C for 3 days.
After three day incubation period, all blood samples
were processed for cell-free RNA analyses and compared
with initial samples which were immediately processed
after blood collection. As shown in Figure 3A, blood
drawn into K3EDTA tubes and stored at 6°C, 22°C or
30°C showed 3-fold, 440-fold and 95-fold increase in
cell-free c-fos mRNA concentration respectively. How-
ever blood drawn into BCTs and stored at 6°C, 22°C or
30°C showed only a slight increase (2-fold, 5-fold and
2-fold respectively) in cell-free c-fos mRNA concentra-
tion (Figure 3A). Figure 3B shows the effect of diffe-
rent temperatures on cell-free plasma β-actin mRNA
concentration. Blood in K3EDTA tubes stored at 6°C,
22°C or 30°C showed 22-fold, 27-fold and 5-fold in-
crease in β-actin mRNA concentration respectively.
Blood in BCTs stored at 6°C, 22°C or 30°C showed no
significant increase in β-action mRNA concentration.
Discussion
Noninvasive molecular assays based on cell-free nucleic
acid markers circulating in blood are becoming increa-
singly important to medical diagnostics. Short-term
storage or transportation of blood samples from the site
of phlebotomy to another facility is commonly required
during assay development or clinical application, e.g.
multicenter clinical trials and shipping of samples from
remote clinics to a central medical laboratory. These
pre-analytical variables might compromise the measure-
ment accuracy of molecular targets such as cell-free
nucleic acids. In our previous study we had demon-
strated that blood drawn into BCTs can be stored at
room temperature for up to 3 days without compromi-
sing the original quantity and quality of cfRNA [11].
Based on these studies, we hypothesized that BCTs
could be used for transportation of blood samples to a
centralized facility for blood processing and cfRNA ana-
lysis. The present study provides experimental evidence
to back this hypothesis. In this study we also explored
the best temperature range that the BCTs would
perform well by stabilizing cfRNA present in a blood
sample. We found that BCT is able to stabilize cfRNAand minimize background RNA release during shipping
and storage temperature fluctuations, whereas, as ex-
pected, the control K3EDTA tubes failed to maintain
circulating cell-free RNA concentrations under the same
conditions.
Shipping blood specimens prior to cfRNA extraction
introduces some pre-analytical variations including
agitation and exposure to temperature changes during
transportation. The amount of agitation is difficult to
control and it may significantly influence accuracy of
nucleic acid-based assays. Shaking could disrupt nucle-
ated blood cell integrity and cellular RNA will release
into plasma contaminating true cfRNA. In addition, it
has been suggested that cfRNA survives in RNase-rich
plasma through a protective mechanism, i.e. within lipo-
protein vesicles such as apoptotic bodies [13]. Potent
enzymes may secret or leak out of cells after shaking
and destroy these vesicles resulting in degradation of
endogenous circulating RNA. Either increase in back-
ground RNA or reduction in original cfRNA will affect
test results. In this comparative study, blood was collec-
ted into un-stabilized control tubes and BCT tubes
containing stabilizing reagents for both cells and cfRNA.
To protect samples, tubes were packed in clam shells
and then shipped in a Styrofoam box which underwent a
48-h round trip at ambient temperature. Our plasma
RNA analysis indicates that cells in BCT withstood
shipping conditions much better than those shipped in
K3EDTA tubes. The BCT showed relatively stable cfRNA
concentrations before and after shipping, whereas
K3EDTA showed dramatic increases in cfRNA under
shipping conditions. This suggests nucleated cell disrup-
tion occurred in blood samples that were shipped in
K3EDTA, which led to cellular RNA release, but this was
minimized in stabilized samples.
Another common post-phlebotomy variable which
needs to be taken into account is variation in sample
storage temperature. In current hematology practice, it
is not uncommon that blood specimens are delivered to
the clinical or research laboratory after a significant
post-collection interval. For instance, this interval may
exceed 48–72 h on weekends. These specimens are
usually kept in a refrigerator or even exposed to room
temperature during transportation prior to processing.
Cell-free nucleic acid-based assays are presumably more
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Figure 3 Effect of storage temperature on cfRNA concentration in blood samples. Blood was drawn into K3EDTA tubes and BCTs (n = 10)
and incubated at 6°C, 22°C or 30°C for 3 days, respectively. Plasma was then separated and cfRNA isolated. The cell free mRNAs for c-fos (A) and
β-actin (B) were quantified by RT-qPCR. A significant increase in mRNA copy numbers for c-fos and β-actin was observed in blood stored in
K3EDTA tubes at 6°C, 22°C and 30°C for 3 days, whereas samples stored in BCTs only showed a slight increase. Box plots show the median
(line inside the box) and 75th and 25th percentiles (limits of the box). The upper and lower error bars indicate the 90th and 10th percentiles,
respectively. The upper most and lower most dots indicate the maximum and minimum values.
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Membrane rigidity of blood cells is expected to increase
as temperature is lowered [14]. A portion of cells may
become fragile and weak. These cells might readily
secret cellular RNA into plasma and cause changes in
cfRNA concentration during cfRNA processing, e.g.
centrifugation. On the other hand, high temperature can
also cause problems by overheating and thus deteriora-
ting ex vivo blood cells. In the shipping study mentioned
above, the box shipped at ambient temperature kept a
relatively stable temperature around 20–24°C during thecourse of shipment. Although there was temperature
elevation up to 29°C, it only occurred for a short period
of time. Therefore, we studied the effect of various
storage temperatures on the cfRNA concentration of
blood drawn into K3EDTA and BCT for a longer time.
Following blood draw, samples were incubated at 6°C,
22°C or 30°C for 3 days. For all storage temperatures, we
observed larger increases in plasma mRNAs in unpres-
erved K3EDTA blood samples as compared to stabilized
BCT blood samples. Our blood smear examination
under a microscope revealed that leukocytes are well
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cant number of leukocytes in K3EDTA samples was
degraded or broken after being incubated at 22°C or 30°C,
resulting in release of considerable amount of cellular
RNA into plasma. The fold-change is smaller at 30°C than
22°C, which might be explained by the possibility that
released RNA and/or cfRNA is degraded more at a higher
temperature because the activity of RNase enzymes could
be higher at 30°C than 22°C or more such enzymes are
released at 30°C. More interestingly, cell-free mRNA
concentrations also increase at 6°C in K3EDTA tubes,
though very few degraded cells have been observed in the
smear preparation. This could be due to possible changes
in rigidity and permeability of cell membrane. Alter-
natively, the stress of low temperature might alter gene
expressions and thereafter affect secretion of these genes.
Taken together, our data demonstrates the ability of the
new blood collection device to stabilize cfRNA levels and
minimize background RNA release across a broad tempe-
rature range for an extended period of time.
Cell-free nucleic acid has the potential to make a
significant impact in non-invasive molecular diagnostics.
Reports on possible clinical utility of cfRNA are growing
[15-17]. Establishing standard protocols is essential for
accurate measurements of cfRNA for assay development
and clinical practice. Thus, streaming sample collection,
transportation and storage is of great significance. To
our knowledge, this is the first study focusing on the
possibility of shipping and storing unprocessed blood
samples for cfRNA analysis. Previous similar investi-
gations have only been done on cellular RNA [18]. The
shipping experiment described in this study has not been
performed in extremely cold or hot conditions. There-
fore, care should be taken to ensure blood specimens are
better not exposed to extreme temperatures during ship-
ping. For example, including gel packs in the shipping
box may be helpful. When blood samples drawn into
BCTs were stored at refrigerated temperature for 3 days,
there was a slight hemolysis in the blood sample. A high
degree of hemolysis occurred when BCT blood samples
were stored at or above 30°C. Therefore, for optimum
results, it is suggested that samples collected in BCTs
should be stored and/or transported at temperatures
between 18–25°C and should be processed within 3 days
after phlebotomy, because the novel chemical cocktail
has been designed to perform optimally at this tempe-
rature range. The effect of potential interfering sub-
stances in blood such as hemoglobin, glucose and lipid
on BCT performance is worth being investigated,
although we have not observed any inconsistencies with
random donors. Another limitation of this study is that
we only tested several cfRNAs. More cell-free RNA
species may need to be examined and validated when
using BCTs, especially disease-associated cfRNAs.In conclusion, our present study demonstrates that
cfRNA concentration in whole blood is unstable after
transportation or storage when samples are collected in
traditional K3EDTA tubes. The newly developed blood
collection tube with stabilizing agents well maintains the
cfRNA level and is suitable for blood shipment and sto-
rage prior to processing. Using this new blood collection
device, shipping or ex vivo storage of blood samples for
up to 3 days become possible, allowing flexibility for
offsite blood draws to be sent to the facilities capable of
downstream analysis of cfRNA without prior centrifuga-
tions or cryopreservation.
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